本文選題：柳杉花粉癥 + 舌下特異性免疫治療��； 參考：《重慶醫(yī)科大學(xué)》2017年碩士論文

【摘要】：背景:用單一的柳杉花粉抗原提取物做舌下特異性免疫治療對(duì)患柳杉花粉癥患者療效仍不確定。目的:通過做系統(tǒng)評(píng)價(jià)和meta分析來評(píng)估舌下特異性免疫治療對(duì)柳杉花粉癥患者的有效性。方法:在MEDLINE、EMBASE和Cochrane數(shù)據(jù)庫中檢索比較舌下特異性免疫治療與安慰劑對(duì)照治療柳杉花粉癥患者的隨機(jī)對(duì)照試驗(yàn),主要的結(jié)局指標(biāo)是癥狀藥物評(píng)分,次要的結(jié)局指標(biāo)是不良反應(yīng)、生活質(zhì)量和血清特異性Ig E和Ig G4的水平。結(jié)果:我們最終納入共計(jì)受試者762個(gè)的4個(gè)隨機(jī)對(duì)照實(shí)驗(yàn)。Meta分析顯示舌下特異性免疫治療組相對(duì)于對(duì)照組明顯降低了受試者的癥狀藥物評(píng)分(standardized mean difference[SMD],-0.94;95%confidence interval[CI],-1.75 to-0.14;P=0.02;I 2=93%),亞組分析顯示在花粉濃度小于(SMD,-2.29;95%CI,-3.64 to-2.16;P.001)或者大于(SMD,-0.36;95%CI,-0.51 to-0.21;P.001;I2=0%)1200/cm 2及治療時(shí)間大于1年(SMD,-0.43;95%CI,-0.59to-0.26;P.001;I 2=0%)的情況下,舌下特異性免疫治療組相對(duì)于對(duì)照組更能改善患者的病情。在共計(jì)405人的實(shí)驗(yàn)組中有237人(58.5%)以及在共計(jì)357人的對(duì)照組有192人(53.8%)報(bào)道出現(xiàn)過不良反應(yīng)。結(jié)論:這個(gè)研究顯示舌下特異性免疫治療對(duì)治療柳杉花粉癥患者有統(tǒng)計(jì)學(xué)上的有效性。然而這些發(fā)現(xiàn)僅基于很少量的隨機(jī)對(duì)照試驗(yàn)分析,后期仍需大樣本和高質(zhì)量的隨機(jī)對(duì)照試驗(yàn)做進(jìn)一步的研究。
[Abstract]:Background: the effect of sublingual specific immunotherapy with a single extract of Cryptomeria chinensis pollen antigen is still uncertain. Objective: to evaluate the efficacy of sublingual specific immunotherapy in patients with Cryptomeria pollinosis by systematic evaluation and meta analysis. Methods: in the database of MEDLINE EMBASE and Cochrane, a randomized controlled trial was conducted to compare sublingual specific immunotherapy with placebo-controlled therapy in patients with Cryptomeria pollen syndrome. The main outcome index was symptomatic drug score, and the secondary outcome index was adverse reaction. Quality of life and serum specific levels of IgE and IgG4. Results: we finally included 762 subjects in 4 randomized controlled trials. Meta-analysis showed that the sublingual specific immunotherapy group significantly decreased the drug score of standardized mean difference [SMD] -0.94c95 confidence interval [CI] -1.75 to 0.14% Pt0.02I2935.The subcomponent of the sublingual specific immunotherapy group was significantly lower than that of the control group. When the pollen concentration is less than SMD-2.29CI-3.64 to-2.16 P.001) or larger than SMD-0.36 ~ 95CI-0.51 to-0.21, P.001and the treatment time is longer than 1 year SMD-0.4395CI-0.59to-0.26 (P.001C), the treatment time is longer than that of SMD-0.4395CI-0.59to-0.26. The sublingual specific immunotherapy group can improve the patient's condition more than the control group. Adverse reactions were reported in 237 of 405 experimental groups and 192 of 357 control groups. Conclusion: this study shows that sublingual specific immunotherapy is statistically effective in the treatment of Cryptomeria pollen syndrome. However, these findings are based on only a small number of randomized controlled trial analyses, and further research is needed at a later stage with large samples and high quality randomized controlled trials.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R765.21

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 許麗娟,張嵩玉,楊強(qiáng),程雷,殷敏,三好彰;武漢城區(qū)柳杉花粉癥發(fā)病的初步研究[J];臨床耳鼻咽喉科雜志;2000年11期

，

本文編號(hào)：1781431